VAUGHAN, ON, Aug. 17, 2015 /CNW/ – Alexion Pharma Canada, a subsidiary of Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that Health Canada has approved Strensiq™ (asfotase alfa) as enzyme replacement therapy for patients with confirmed diagnosis of paediatric-onset hypophosphatasia (HPP). Strensiq is the first approved treatment for HPP, an ultra-rare, genetic, metabolic disease in which patients experience devastating, progressive effects on multiple organs of the body, leading to debilitating morbidities or pre-mature mortality.
Full Article Here: www.newswire.ca
The post Health Canada Approves Vaughan Based Pharmaceutical Company Alexion Pharma Canada’s Strensiq™, the First Therapy for Patients with Hypophosphatasia appeared first on Toronto Area's Tech Hub.